RARX - Ra Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
2,500
2,500
0
4,928
4,094
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
61,928
54,449
45,251
27,928
15,217
Selling General and Administrative
17,046
14,439
9,778
5,024
2,233
Total Operating Expenses
78,974
68,888
55,029
32,952
17,450
Operating Income or Loss
-76,474
-66,388
-55,029
-28,024
-13,356
Interest Expense
-
-
0
0
159
Total Other Income/Expenses Net
1,356
-38
-74
-967
-447
Income Before Tax
-73,654
-64,962
-54,458
-28,882
-13,962
Income Tax Expense
-
-19
-19
-18
-19
Income from Continuing Operations
-73,635
-64,943
-54,439
-28,864
-13,943
Net Income
-73,635
-64,943
-54,439
-28,864
-13,943
Net Income available to common shareholders
-73,635
-64,943
-54,439
-28,864
-10,734
Reported EPS
Basic
-
-2.06
-2.41
-6.98
-1.39
Diluted
-
-2.06
-2.41
-6.98
-1.39
Weighted average shares outstanding
Basic
-
31,542
22,591
4,135
7,721
Diluted
-
31,542
22,591
4,135
7,721
EBITDA
-
-64,791
-52,934
-27,608
-12,906